U S Stem Cell Inc Quick Ratio (USRM) starting from the fourth quarter 2022 to fourth quarter 2021, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
U s Stem Cell Inc   (NONE: USRM)
    Sector • Healthcare    Industry • Medical Laboratories
   Industry • Medical Laboratories
   Sector • Healthcare

U S Stem Cell Inc 's Quick Ratio

USRM's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the fourth quarter 2022, Quick Ratio fell to 0 a new company low.

Within Medical Laboratories industry 54 other companies have achieved higher Quick Ratio than U S Stem Cell Inc in fourth quarter 2022. While Quick Ratio total ranking in the fourth quarter 2022 has deteriorated compared to the prior quarter from 5762 to 5833.

Explain Quick Ratio?
How much Cash & cash equivalents USRM´s has?
What are USRM´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

USRM Quick Ratio (Dec 31 2022)
Q4		 (Sep 30 2022)
Q3		 (Jun 30 2022)
Q2		 (Mar 31 2022)
Q1		 (Dec 31 2021)
Q4
Y / Y Current Liabilities Change 16.94 % 17.14 % 16.72 % 16.26 % 0.3 %
Y / Y Cash & cash equivalent Change -86.97 % -0.59 % -92.51 % -96.74 % 112.13 %
Quick Ratio MRQ 0 0 0 0 0
USRM's Total Ranking # 5833 # 5762 # 5797 # 5129 # 5728
Seq. Current Liabilities Change 3.3 % 3.45 % 3.38 % 5.84 % 3.48 %
Seq. Cash & cash equivalent Change -82.98 % 191.95 % -28.61 % -63.27 % 29.85 %



Quick Ratio fourth quarter 2022 Company Ranking
Within: No.
Medical Laboratories Industry # 55
Healthcare Sector # 1258
Overall Market # 5833


Quick Ratio Statistics
High Average Low
0.26 0.05 0
(Mar 31 2018)   (Sep 30 2012)




Financial Statements
U S Stem Cell Inc 's Current Liabilities $ 14 Millions Visit USRM's Balance sheet
U S Stem Cell Inc 's Cash & cash equivalent $ 0 Millions Visit USRM's Balance sheet
Source of USRM's Sales Visit USRM's Sales by Geography


Cumulative U S Stem Cell Inc 's Quick Ratio

USRM's Quick Ratio for the trailling 12 Months

USRM Quick Ratio

 (Dec 31 2022)
12 Months		 (Sep 30 2022)
12 Months		 (Jun 30 2022)
12 Months		 (Mar 31 2022)
12 Months		 (Dec 31 2021)
12 Months
Y / Y Current Liabilities TTM Growth 16.77 % 12.42 % 14.42 % 14.64 % 15.32 %
Y / Y Cash & cash equivalent TTM Growth -90.78 % -85.05 % -86.14 % -68.13 % 129.63 %
Quick Ratio TTM 0 0 0 0 0.01
Total Ranking TTM # 4927 # 4776 # 5021 # 5125 # 5026
Seq. Current Liabilities TTM Growth 3.95 % 4.02 % 3.96 % 3.88 % 0.08 %
Seq. Cash & cash equivalent TTM Growth -36.31 % -0.19 % -57.45 % -65.92 % 3.3 %

Quick ratio ranking by company, industry and sector >> Back to USRM Financial Strength Comparisons >> Go to Compare USRM Quick Ratio to its Competitors

On the trailing twelve months basis In Spite of the rise in Current Liabilities in the Q4 2022 to $14.08 millions, cumulative Quick Ratio